In this issue:
- Adjusted vs. continuous Rd for elderly, intermediate-fit, newly diagnosed MM
- Novel combinations for lenalidomide-refractory MM
- PCD for relapsed/refractory MM
- Isatuximab-carfilzomibdexamethasone in relapsed MM
- Temporal changes of MM care costs in Denmark and Sweden
- Subcutaneous daratumumab formulation for relapsed/refractory MM
- MRD dynamics with continuous lenalidomide maintenance for MM
- TOURMALINE-MM1 final OS analysis
- Daratumumab-pomalidomidedexamethasone in previously treated MM
- Weekly carfilzomib-lenalidomidedexamethasone-daratumumab in newly diagnosed MM
Please login below to download this issue (PDF)